¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼­¿ï¾Æ»êº´¿ø Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦35Â÷ KSTH Ãá°èÇмú´ëȸ : 2019-05-24

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼­¿ï¾Æ»êº´¿ø Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦35Â÷ KSTH Ãá°èÇмú´ëȸ : 2019-05-24
±³À°ÀÏÀÚ : 2019-05-24
±³À°Àå¼Ò : ¼­¿ï¾Æ»êº´¿ø ±³À°¿¬±¸°ü ÁöÇÏ1Ãþ ´ë°­´ç, ¼Ò°­´ç  
±³À°ÁÖÁ¦ : Á¦35Â÷ KSTH Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ
´ã´çÀÚ : ±èÁø¾Æ
¿¬¶ôó : 042-484-2426  
À̸ÞÀÏ : ksth@thrombo.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤½Å°Ç°­ÀÇÇаú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаúÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·á»çȸ½É¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥, ÀÇ·á°æ¿µ, ±âŸ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 40,000¿ø      
ºñ°í »çÀüµî·Ïºñ 3¸¸¿ø, Àü°øÀÇ ¹× ±âŸ 1¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ09:30~09:50 ´ë±Ô¸ð Àα¸µ¥ÀÌÅÍ º£À̽º·Î º» Çѱ¹ÀÎ ½É¹æ¼¼µ¿°ú NOAC »ç¿ëÀÇ Æ¯¼º  À̼ҷÉ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ09:50~10:10 2018 ´ëÇѺÎÁ¤¸Æ ÇÐȸ ºñÆǸ·¼º ½É¹æ¼¼µ¿ ȯÀÚÀÇ ³úÁ¹Áß ¿¹¹æ Áöħ  Á¤º¸¿µ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ10:10~10:30 ½ÉÀå ³» Ç÷Àü Çü¼ºÀº Ç÷°ü ³» Ç÷Àü Çü¼º°ú ¾î¶»°Ô ±¸º°µÇ´Â°¡? Journey to the beyond NOACs  ±èÄ¡°æ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ10:30~11:00 ¡°East Asian Paradox¡± and update of recent evidences  ¹Ú°æ¿ì(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ11:00~11:30 The role of erythrocyte in arterial thrombosis  À̺´±Ç(¿¬¼¼ÀÇ´ë) 
È޽Ġ05-24  11:30~11:50 break  () 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ11:50~12:10 What¡¯s the optimal antiplatelet strategies in PAD?  °í¿µ±¹(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ12:10~12:30 What¡¯s the role of NOAC in PAD?  ¹Ú»óÈ£(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ12:30~12:50 Current best interventional practice for the treatment of acute VTE  º¯½ÂÀç(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ12:50~13:00 Unmet needs and management strategies on DAPT initiation for ACS patients  ±èÇö±¹(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ13:00~13:10 New treatment option for SGLT2 inhibitor in patients with T2DM  ½ÉµÎ¼±(Àü³²ÀÇ´ë) 
½Ä»ç 05-24  13:10~14:00 Á¡½É½Ä»ç  () 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ14:00~15:00 Poster Oral presentation  ¾È¿µ±Ù(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ15:00~15:30 Patient and anticoagulation dose selection for extended treatment in VTE  ³ª»óÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ15:30~16:00 Balloon pulmonary angioplasty in CTEPH management  °­µµÀ±(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ16:00~16:20 Practical guide for management of splanchnic vein thrombosis  ÀÌÁöÇö(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ16:20~16:40 What is the standard to extend the anticoagulation duration in patient with cancer associated thrombosis?  ÀÓÈ£¿µ(ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 05-24 ´ë°­ÀǽǠ16:40~17:00 Is it possible to use DOACs in patients with end-stage renal disease on hemodialysis?  È²Çå±Ô(¼øõÇâÀÇ´ë) 
±âŸ 05-24 ´ë°­ÀǽǠ17:00~17:20 Çмú»ó ¹ßÇ¥ ¹× ½Ã»ó  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼­¿ï¾Æ»êº´¿ø Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦35Â÷ KSTH Ãá°èÇмú´ëȸ : 2019-05-24""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѽÅÀåÇÐȸ KSN 2019 : 2019-05-24
´ÙÀ½±Û ºÎ»ê´ëÇб³º´¿ø ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ºÎ¿ï°æÁöȸ 5¿ù ¿¬¼ö°­Á : 2019-05-23
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 2 20:07:21
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 2 20:05:30
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 2 20:04:03
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 2 20:01:45
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 0 19:59:34
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 0 19:57:58
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 0 19:56:02
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 0 19:54:40
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 0 19:53:14
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 0 19:51:56
20883 ¼­¿ï 2024 ¼±Ãµ¼º Ⱦ°æ¸· Å»Àå ÄÚȣƮ (K-CDH) ±³À°¼¼¹Ì³ª : 2024-06-29 0 0 19:50:05
20882 ¼­¿ï 2024 ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-29 0 0 19:49:01
20881 °­¿ø 2024 ³âµµ Á¤Çü¿Ü°úÇб³½Ç °³¿øÀÇ¿¬¼ö°­Á : 2024-06-29 0 0 19:47:48
20880 ¼­¿ï (¿Â¶óÀÎ) 2024 ¸¶Æ÷±¸ÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-29 0 0 19:46:34
20879 ¼­¿ï Á¦10ȸ ¿ëºÀÀÇÇÐȸ Çмú´ëȸ : 2024-06-29 0 0 19:45:15
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷